Basilea Presents Anti-Infective Pipeline and Late-Stage Development Plans

By Public Technologies
  • Basilea reported Cresemba in-market sales of USD 817 million for July 2025-June 2026, up 25% year over year.
  • Fosmanogepix phase 3 studies are ongoing in invasive candidiasis and invasive mold infections.
  • Ceftibuten-ledaborbactam's phase 2/3 program in complicated urinary tract infections is scheduled to start in mid-2027.
  • Zevtera's US market exclusivity runs until April 2034, supporting its long-term growth opportunity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.